Learn Before
Concept

Methods of CoVLP Phase 1 Trial

  • A randomized, partially-blinded, prime-boost, 21 days apart, dose escalation phase 1 study
  • one 3.75, 7.5 or 15 µg dose admininstered intramuscularly alone or with CpG1018 or AS03
  • Participants were SARS-CoV-2 seronegative adults between the ages of 18-55 years
  • Primary endpoints of safety and immunogenicity were reported until 42 days after vaccine administration
  • The presence of neutralizing antibodies was determined using a "VSV pseudovirus assay and cellular responses by ELISpot (IFNγ, IL-4)"

0

1

Updated 2020-11-23

Contributors are:

Who are from:

Tags

SARS-CoV-2 (COVID-19)

Biomedical Sciences